{
    "patientData": {
        "name": "Sarah Miller",
        "mrn": "MC-001001",
        "age_sex": "63-year-old Female",
        "date_of_summary": "November 15, 2025",
        "one_sentence_impression": "Sarah Miller has severe acute liver injury with acute liver failure, most likely drug-induced by Trimethoprim-Sulfamethoxazole, potentiated by chronic Methotrexate use, requiring urgent ICU management and multidisciplinary care.",
        "clinical_context_baseline": {
            "comorbidities": [
                "Rheumatoid arthritis",
                "Essential hypertension",
                "Mild chronic kidney disease"
            ],
            "key_baseline_labs": "Baseline labs (prior to 2025-06-15) showed stable renal function (eGFR ~58-85 mL/min/1.73m2), normal LFTs (ALT/AST <40 U/L, Total Bilirubin <1.2 mg/dL), and normal CBC/platelets.",
            "social_history": "Regular alcohol consumption (7-14 units/week); ex-smoker (quit 2017, 20 pack-year history). Retired carpenter."
        },
        "suspect_drug_timeline": {
            "chief_complaint": "Severe fatigue, jaundice, epigastric pain, confusion, and nausea.",
            "hopi_significant_points": "63-year-old female with RA on MTX and HTN on Lisinopril presented with acute onset of severe fatigue, jaundice, epigastric pain, and confusion starting ~6 days after initiating Trimethoprim-Sulfamethoxazole for sinusitis. Noted oral mucosal ulcerations.",
            "chronic_medications": [
                "Methotrexate 20 mg PO weekly",
                "Folic Acid 5 mg PO weekly",
                "Lisinopril 10 mg PO daily"
            ],
            "acute_medication_onset": "Trimethoprim-Sulfamethoxazole 800/160 mg PO BID, started on 2025-06-15 for sinusitis.",
            "possibilities_for_dili": [
                "Trimethoprim-Sulfamethoxazole",
                "Methotrexate"
            ]
        },
        "rule_out_complete": {
            "viral_hepatitis": "Pending (HAV IgM, HBsAg/IgM, HCV Ab ordered).",
            "autoimmune": "Workup pending; low suspicion given acute onset and clear drug exposure.",
            "other_competing_dx_ruled_out": "No signs or symptoms suggestive of sepsis, ischemic hepatitis, Wilson's disease, or significant alcohol-related liver disease (beyond contributing risk factor) at presentation."
        },
        "injury_pattern_trends": {
            "pattern": "Hepatocellular (ALT 1650 U/L, AST 2100 U/L, ALT/ULN : AST/ULN ratio ~0.56).",
            "hys_law": "Hy's Law criteria are met or strongly suggested: Marked elevation in transaminases (>3x ULN) with significant jaundice (Total Bilirubin >3x ULN) and likely coagulopathy (INR potentially >1.5, though INR 1.0 on presentation, trends are critical), in the setting of drug exposure. This indicates a high risk for severe outcomes.",
            "meld_na": "Based on current presentation (high bilirubin, likely elevated creatinine), MELD-Na score would be elevated, suggesting significant liver dysfunction and poor prognosis without intervention. Precise calculation pending full results, but likely >15-20.",
            "lft_data_peak_onset": {
                "ALT": "1650 U/L",
                "AST": "2100 U/L",
                "Alk_Phos": "350 U/L",
                "T_Bili": "12.5 mg/dL",
                "INR": "1.0"
            },
            "lft_sparklines_trends": "Labs show a dramatic acute rise in ALT, AST, Total Bilirubin, and Alkaline Phosphatase following TMP-SMX initiation, consistent with acute DILI.",
            "complications": [
                "Hepatic Encephalopathy (Grade 4 - disorientation, asterixis)",
                "Acute Liver Failure",
                "Oral mucosal ulcerations",
                "Acute Kidney Injury (Creatinine 1.5 mg/dL, eGFR 58)"
            ],
            "noh_graz_law": "Not applicable as the primary suspected agent is not Acetaminophen."
        },
        "severity_prognosis": {
            "severity_features": [
                "Hepatic Encephalopathy (GCS 13)",
                "Severe Jaundice (Total Bilirubin 12.5 mg/dL)",
                "Marked Transaminase Elevation (ALT 1650, AST 2100)",
                "Acute Kidney Injury",
                "Potential for rapid progression of coagulopathy",
                "Requiring ICU admission"
            ],
            "prognosis_statement": "The patient has severe acute liver injury meeting criteria for acute liver failure, carrying a significant risk of mortality or need for liver transplantation if liver function does not rapidly improve. Prognosis is guarded and dependent on rapid intervention and supportive care."
        },
        "key_diagnostics": {
            "imaging_performed": "Abdominal Ultrasound (2025-06-22) showed minimal IVC collapsibility, suggesting adequate intravascular volume but did not assess the liver parenchyma or biliary tree directly. Abdominal CT and MRI reports were not retrieved.",
            "biopsy": "Liver biopsy not performed at presentation but may be considered if diagnosis remains uncertain or recovery is atypical.",
            "methotrexate_level": "Ordered urgently on presentation (2025-06-21); results pending."
        },
        "management_monitoring": {
            "stopped_culprit_drugs": [
                "Trimethoprim-Sulfamethoxazole",
                "Methotrexate"
            ],
            "active_treatments": [
                "Intravenous fluids",
                "N-acetylcysteine (IV)",
                "Ongoing supportive care in ICU"
            ],
            "consults_initiated": [
                "Hepatology",
                "Gastroenterology",
                "Hematology",
                "Intensive Care Unit (ICU)"
            ],
            "nutrition": "NPO initially, transitioning to appropriate nutritional support under dietician guidance, carefully considering hepatic and renal function.",
            "vte_ppx": "Initiated based on ICU admission and acute illness status.",
            "causality_rucam": "RUCAM score not explicitly calculated, but clinical features are highly suggestive of probable DILI from TMP-SMX, potentiated by Methotrexate, based on temporal association, known hepatotoxicity, and exclusion of other causes.",
            "monitoring_plan": [
                "Liver function tests (ALT, AST, Bilirubin, INR) every 12-24 hours",
                "Renal function and electrolytes",
                "Neurological status checks (frequent)",
                "Vital signs monitoring",
                "Hematologic parameters (CBC, platelets)"
            ]
        },
        "current_status_last_48h": "Critically ill in ICU with severe acute liver injury and hepatic encephalopathy. Close monitoring and supportive care are ongoing. Response to NAC and withdrawal of offending agents is being assessed."
    },
    "zone": "patient-report-zone"
}